View clinical trials related to Influenza, Human.
Filter by:Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
A phase I/II trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a single intramuscular injection of plant-based Seasonal Quadrivalent VLP Influenza Vaccine administered to healthy adults 18-49 years of age. A total of one hundred and twenty (120) subjects will be randomized in four (4) groups of 30 subjects to receive one injection of either a low, a medium, or a high dose level of VLP of the quadrivalent VLP influenza vaccine or the placebo preparation (100 millimolar (mM) phosphate buffer + 150 mM sodium chloride (NaCl) + 0.01% Tween 80).
A phase 2, Randomized, Observer-blind, Multicenter, Dose-Ranging Study to Evaluate the Immunogenicity, Safety, and Tolerability of the plant-made H5 VLP Influenza vaccine adjuvanted with Alhydrogel or Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE), in healthy adults 18-60 years of age.
The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
This is a phase I study to evaluate the safety of a vaccine to protect against influenza viruses of the H2N2 subtype. A total of 40 adults will be enrolled and receive two doses of vaccine or placebo one month apart.
The purpose of this pilot research project is to look at the effect of the inactivated influenza vaccine (seasonal flu shot) on early signs of immune or germ-fighting response known as cytokines or signal molecules. The investigators also want to see if the timing of vaccine administration has any effect on women's reproductive hormones. The investigators hypothesis is that influenza vaccine given right before ovulation may change the hormone levels usually seen after ovulation. Thi
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
In this study, the investigators will prospectively assess fever rates and other adverse events in pregnant women after administration of inactivated influenza vaccine (IIV) using text messaging. The investigators hypothesize that women <20 weeks gestational age who receive IIV will be willing to enroll in a text messaging-based vaccine adverse event monitoring program and will use it to report fever in the post-vaccination period as well as continue to text pregnancy-related outcomes through the end of their pregnancy.
Background: - Researchers want to know if a certain type of antibody in the blood affects whether people get influenza (the flu). They will study 2 different groups with different levels of anti-HA antibodies and expose them to the flu virus. They will study how the flu develops in a healthy person. This may lead to future studies to develop new vaccines and treatments for the flu. Objective: - To study how people can be protected from flu infection. Eligibility: - Healthy volunteers 18 to 50 years of age. Design: - Participants will be screened through the use of a medical history, physical exam, and laboratory tests. - Groups of 7 participants will stay in an isolation unit in a hospital for at least 9 days with no visitors. - Participants will be screened again upon admission. They will also have: - ECG: soft electrodes will be stuck to the skin. A machine will record the heart s electrical signals. - Echocardiogram: a small probe will be held to the chest to take pictures of the heart. - Lung tests: participants will blow into a machine. - They will also have nasal fluid collected. This will be done either with a swab or with a tube of water washing out the nose. This will be done once every day. - The flu virus will be sprayed into the participant s nose. This will be done only once. - Participants will complete a questionnaire on day 1 and twice a day after that for 14 days. - A medical team will watch participants 24 hours a day. They will go home after 2 days of negative flu tests. - Participants will have 4 follow-up visits over 8 weeks.
The aim of the study is to describe the immunogenicity and safety of the new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season in the Northern Hemisphere (NH) in subjects aged 9 to 17 years in Taiwan Primary Objective: - To describe the immunogenicity of the QIV (split-virion, inactivated) NH seasonal formulation Secondary Objective: - To describe the safety of the QIV (split-virion, inactivated) NH seasonal formulation